



SARS-CoV-2 Vaccination in Transplant Recipients

Guest Editors:

Dr. Sam Kant

Johns Hopkins School of
Medicine, Baltimore, MD, USA

Prof. Dr. Daniel Brennan

Medical Director, Comprehensive
Transplant Center, The Johns
Hopkins Hospital, Baltimore, MD,
USA

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

Recipients of solid organ transplants are at a high risk of developing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated complications. The introduction of targeted vaccines has mitigated the risk of developing infection, albeit with a continued suboptimal response in comparison to the general population. This suboptimal response is mostly attributable to the use of maintenance immunosuppression to prevent organ rejection. This issue will cover the following pertinent aspects of the SARS-CoV-2 vaccine in recipients of solid organ transplantation:

1. Track the arc of development of the SARS-CoV-2 vaccines and their use in recipients of solid organ transplants;
2. Review vaccine response in transplant recipients focused on each type of solid organ transplantation;
3. Methods of monitoring immune response to vaccines;
4. Measures to reduce the risk of infection in patients with an absent/reduced response to vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com